Candel Therapeutics (NASDAQ:CADL) Cut to Neutral at Bank of America
Bank of America downgraded shares of Candel Therapeutics (NASDAQ:CADL – Free Report) from a buy rating to a neutral rating in a research report report published on Wednesday, Marketbeat.com reports. The brokerage currently has $7.00 price objective on the stock, down from their prior price objective of $13.00. Several other research analysts also recently weighed […]
More Stories
Trump Urges Cuba to Strike Deal With US After Oil, Money Cut Off From Venezuela
By Jacob Burg U.S. President Donald Trump on Jan. 11 told Cuba that it should forge a deal with the...
Wall Street Review: Stocks Close Out Strong Week on Labor Market Clarity
By Panos Mourdoukoutas Equities resumed their rally this week as investors gained a clearer view of the labor market following...
Protests Spread in Iran as Regime Vows to Retaliate Against Any US Attack
By Jacob Burg The Iranian regime threatened on Jan. 11 to strike Israeli and U.S. military bases if Washington attacks...
ICE Agent Involved in Shooting Is Getting Death Threats, Border Czar Says
By Jack Phillips White House border czar Tom Homan defended Immigration and Customs Enforcement (ICE) amid protests against the agency...
Overhauling Air Traffic Control Involves 5,000 Locations and 600 Radar Systems—What to Know
By Jacob Burg The federal government is embarking on what Transportation Secretary Sean Duffy has called “the most important infrastructure...
Trump Calls for Temporary 10 Percent Cap on Credit Card Interest Rates
By Aldgra Fredly President Donald Trump said on Jan. 9 that he would call for a one-year cap on credit...